ArticleAdvances in therapy2026

Cost Per Remission of Vedolizumab Versus Risankizumab for the Treatment of Moderately to Severely Active Crohn's Disease in Italy.

Elizabeth Brook et al.PubMed ↗Publisher ↗

No numbers read from the abstract.